The human polyomavirus BK (BKV) is oncogenic in rodents and induces malignant transformation of rodent cells in vitro. Although its role in human tumorigenesis is still debated, BKV represents an excellent model to evaluate molecularly targeted antineoplastic approaches. Here, we have tested whether stable suppression of the T antigen (T-ag) oncogene expression could inhibit the in vitro and in vivo malignant phenotype of BKV-transformed mouse cells. An adenovirus vector system that expresses small hairpin RNAs (shRNAs), which are converted into active small interfering RNAs (siRNA) molecules against the BKV T-ag, was developed. This vector was able to inhibit the expression of BKV T-ag through a highly efficient in vitro and in vivo delivery of the siRNA molecule. In addition, it allowed a stable expression of siRNA for a period of time sufficient to elicit a biological effect. Inhibition of T-ag expression results in reduction of the in vitro growth rate of BKV-transformed cells, which is, at least in part, caused by restoration of p53 activity and induction of apoptosis. In vivo studies proved that adenovirus vectors expressing anti-T-ag siRNA were able to suppress tumorigenicity of BKV-transformed cells. Moreover, adenovirus vector direct treatment of growing tumors resulted in a significant reduction of tumor growth. This study indicates that siRNAs delivery via a viral vector have a potential usefulness as in vivo anticancer tool against viral and cellular oncogenes.
Introduction
BK virus (BKV) is a human polyomavirus with in vitro transforming activity for rodent and human cells 1, 2 and it is oncogenic in hamster, mice and rats. [3] [4] [5] [6] In vitrotransformed rodent cells are immortalized and produce tumors in syngenic animals or nude mice. Association of BKV-DNA with human neoplasms has been reported, although its role in human tumorigenesis is still debated. 7 Similar to the highly homologous simian virus 40 (SV40), the early region of BKV genome encodes two proteins, large T (T-ag) and small t (t-ag) antigens, which behave as oncogenes and are responsible for the viral transforming and oncogenic activities. The transforming and oncogenic activities of T-ag are associated with its ability to bind and block the functions of the tumor suppressor proteins p53 and pRb family members (pRb1, p107 and p130). [8] [9] [10] [11] Studies on the role of t-ag in transformation indicate that although it cooperates with T-ag it is not essential for BKV-transforming properties. Indeed, a lower efficiency of stable transformation and a reduced tumor incidence associated with a longer latency were described as properties of a naturally occurring BKV variant, BKV-IR, lacking the carboxy-terminus of the t-ag. 12, 13 The continuous expression of a functional T-ag, detectable in all BKV-transformed cells, is necessary for the maintenance of transformation.
14 Likewise, studies on the highly homologous SV40 virus have demonstrated that T-ag expression is necessary for the maintenance of transformation [15] [16] [17] [18] and its inhibition by antisense RNA in SV40-positive human mesothelioma cells restores p53 function and induces cell growth arrest and apoptosis. 19 Hence, stable suppression of T-ag expression in BKVtransformed cells should also suppress the in vitro and in vivo-transformed phenotype, making this a model for understanding the underlying molecular pathogenesis and for investigating approaches of molecular anticancer therapy. RNA interference (RNAi), a sequence-specific post-transcriptional gene silencing process initiated by double-stranded RNA (dsRNA), has become a powerful tool to inhibit expression of specific genes in whole organisms or cell lines. [20] [21] [22] Short (21-23 nt) RNA duplexes, generated by the RNase III-type enzyme Dicer, 23, 24 called small interfering RNAs (siRNAs) 25, 26 assemble into the complex RISC (RNA-induced silencing complex), which is responsible for the degradation of target RNAs that contain homologous sequences. In the present study, we tested if the down-modulation of BKV T-ag by siRNA molecules results in suppression of the transformed and oncogenic phenotype.
Materials and methods
Design and transfection of siRNA siRNAs were designed to target the coding sequence of the BKV T-ag in accordance with described criteria, 27 which included a GC content between 30 and 70%, 100 nt downstream to the start codon and target uniqueness as verified by alignment to the expressed sequence databases. Sense and antisense 19-nt RNAs with 2-nt deoxythimidine 3 0 overhangs were designed. BKVT_1390 sense -GGU GUA GCU AUA GAU CAG UdTdT; BKVT_1390 antisense -ACU GAU CUA UAG CUA CAC CdTdT; BKVT _714 sense -CUA GAG AUC CAU ACC AUA CdTdT; BKVT _714 antisense -GUA UGG UAU GGA UCU CUA GdTdT; BKVT_406 sense -GAC CCU AAA GAC UUU CCC UdTdT; BKVT_406 antisense -AGG GAA AGU CUU UAG GGU CdTdT. RNA duplexes were obtained from Dharmacon Inc. (Lafayette, CO, USA) RNA duplex transfection was carried out by using Oligofectamine (Invitrogen, Carlsbad, CA, USA), in accordance with the manufacturer's indications.
Cell lines
The human embryonic kidney cell line 293T was obtained from the American Type Culture Collection (Manassas, VA). The pRPc cell line is a malignant BK virustransformed cell line previously established in our laboratory from normal Balb/c mouse fibroblasts. 28 pRPc cells constitutively express the BKV T-ag. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin and streptomycin.
Plasmid vectors
The vectors for siRNA expression were assembled starting from the psiRNA-hH1GFPzeoG2 plasmid backbone (Invitrogen), which was modified by insertion of a BamHI site upstream to the H1 promoter cassette. Then, the BamHI-SwaI 1-kb fragment of the psiRNA-hH1 G2-BamHI plasmid was cloned into the BamHI and EcoRV sites of the pENTR11 plasmid (Invitrogen), preliminarily modified to abolish a unique BbsI restriction site. The resulting pENTR-psiRNA vector contains bacteriophage Lambda-derived DNA recombination sequences (attL1 and attL2 sites), and two expression units: an siRNA expression cassette, controlled by the polymerase III H1 promoter and a green fluorescent protein (GFP-zeo) expression cassette, where the reporter GFP-zeo gene is transcribed under the control of the hEF1/HTLV1 promoter. 29, 30 For siRNA expression, in vitro-annealed complementary oligonucleotides homologous to target sequences are inserted into the two BbsI sites downstream the human H1 promoter. The two selected siRNA target sequences were BKVT_1390 and BKVT_714. Two complementary oligonucleotides, acctca-(target sense)-TCAAGAG-(target antisense)-TTT and caaaAAA-(target sense)-CTCTTGA-(target antisense)-TG, were synthesized for each target sequence and annealed in vitro. The annealed double-stranded oligonucleotides, with 5 0 protruding ends complementary to the two BbsI sites, were then subcloned into the two BbsI sites of the pENTR-psiRNA vector, generating a vector that could transcribe a short hairpin RNA (shRNA) under direction of the human H1 promoter. A vector, pAd-shControl, containing a scrambled hairpin was designed as a control. The scrambled hairpin was produced by the complementary oligonucleotides 5 0 -acc tca GCT GGA CAT TGA CGA GAC AGA tca aga g TC TGT CTC GTC AAT GTC CAG C ttt-3 0 and 5 0 -caa a GCT GGA CAT TGA CGA GAC AGA ctc ttg a TC TGT CTC GTC AAT GTC CAG C tg-3 0 , which were annealed and inserted into the BbsI site of the pENTR-psiRNA vector. An empty vector, with the H1 promoter and transcriptional termination signals, but lacking a hairpin encoding sequence, was also used as control.
Adenoviral vectors
The adenoviral vectors for siRNA expression were constructed from the pAD/CMV/V5-DEST vector (Invitrogen), which is based on the E1 and E3-deleted human adenovirus, serotype 5. This adenoviral vector contains bacteriophage Lambda-derived DNA recombination sequences (attR1 and attR2 sites) that permit cloning through a site-specific recombination reaction with the attL1 and attL2 sites of the pENTR-psiRNA plasmid. Following site-specific recombination, the resulting vectors pAd_sh1390 and pAd_sh714 were transfected into the complementing 293T cells to produce adenovirus particles. Two adenoviruses were produced and used as controls: the Adeno-GFP, lacking any short hairpin sequence, and the Adeno-shControl, which expresses a scrambled short hairpin sequence (see Plasmid vectors section). In vitro growth assay Four Â 10 4 pRPc cells were seeded in a 1 cm-diameter multi-well plate. Cells were either left uninfected or infected with Adeno-GFP, Adeno-shControl, Adenosh714 or Adeno-sh1390 at a multiplicity of infection (MOI) of 5, 10, 30 and 100 VPPF. Each condition was analyzed in triplicate. The number of living cells was determined at 24, 48 and 72 h after infection by trypan blue staining.
In vivo tumorigenicity assay Pathogen-free BALB/c mice were obtained from the Charles River Laboratories. Twenty-four hours after birth, mice were subcutaneously injected in the back with 2 Â 10 5 pRPc cells. Cells were either uninfected, infected with Adeno-GFP, Adeno-shControl or with a combination (1:1 ratio) of Adeno-sh1390 and Adeno-sh714 at an MOI of 10 VPPF. Tumor growth was monitored every 2 days for 31 days by measuring tumor size with a caliper. The research has complied with institutional policies on animal use.
Tumor growth inhibition 3 Â 10 6 viral particles were injected every 2 days at the site of pRPc cells subcutaneously in or directly into growing tumor nodules. Tumor growth was monitored every 2 days for 31 days by measuring tumor size with a caliper.
Statistical analysis
Results related to in vitro cell growth and size of tumors were averaged and differences among groups were evaluated by t-test. Differences were considered significant at Po0.05.
Results
Suppression of T-ag expression by specific siRNA and shRNA molecules Preliminary studies aimed at the identification of siRNAs with optimal inhibitory activity were carried out by the use of three synthetic siRNAs (siBKVT-406, siBKVT-1390 and siBKVT-714) designed from different sequences of the T-ag target mRNA. The three molecules were transfected in the BKV-transformed cell line pRPc. Immunofluorescence revealed that T-ag expression was reduced or abolished depending on the siRNA. Differences in the level of T-ag silencing was expected as it varies depending on the target sequence. 31 siRNA 1390 and 714 were found to abolish T-ag expression, and were chosen for further experiments.
siRNAs are short-living molecules. However, stable siRNA molecules can be produced in mammalian cells via shRNA intermediates expressed under the control of the polymerase III-dependent H1-RNA promoter, 32 suggesting that expression vectors could be usefully employed to obtain a stable siRNA-mediated antioncogenic activity. Complementary oligonucleotides, containing the 19-nt target sequence, separated by a 7-mer loop from a 19-nt reverse complementary sequence were synthesized, annealed and cloned into the BbsI site of the psiRNA-hH1GFPzeoG2 vector, resulting in the vectors p-sh714 and p-sh1390. Twenty-four hours after transfection into pRPc cells, immunofluorescence analysis revealed that GFP-positive cells had a simultaneous marked reduction of the nuclear rhodamine fluorescence for T-ag, demonstrating that shBKVT-1390 and shBKVT-714 were both active in suppressing T-ag expression. These results established the basis for further experiments using more delivery-efficient viral vectors.
A new adenoviral vector expressing shRNAs anti-BKV T-ag can efficiently silence T-ag and inhibit BKV-transformed cell growth in vitro As functional cellular effects of mRNA inhibition require high gene-transfer efficiency, which cannot be achieved by plasmid transfection strategies, an adenoviral vector able to express siRNA molecules was developed (Figure 1 
The resulting pENTR-sh1390 and the pENTR-sh714 (together defined as pENTR-shBKVT in Figure 1 ) contain the anti-BKV T-ag shRNA-expressing cassette, the reporter gene GFP and the attL1-attL2 elements that allow site-specific recombination with the attR1-attR2 elements of the pAd/CMV/V5-DEST vector. Following site-specific recombination, the resulting vectors pAdsh1390 and pAd-sh714 were transfected into the complementing 293T cells to produce adenovirus particles. Adenovirus vectors lacking a short hairpin sequence, pAd-GFP, or expressing a scrambled sequence, pAdshControl, were also produced.
PRPc cells were transduced with the recombinant adenoviruses and the expression of T-ag was evaluated by immunofluorescence and Western blot 24 and 48 h after infection. As shown by the expression of the GFP reporter gene, the cells were efficiently infected and, at the same time, T-ag expression was inhibited (Figure 1) .
On this basis, we tested the ability of the silencing adenoviruses to induce a biological effect in BKVtransformed cells. PRPc cells were infected at an MOI of 5, 10, 30 and 100 VPPF with Adeno-sh1390 and Adeno-sh714. The number of living cells was scored at 24, 48 and 72 h post-infection. Two adenoviruses were used as control: the Adeno-GFP, lacking a shRNA sequence, and the Adeno-shControl, expressing a scrambled shRNA sequence. The growth rate of pRPc cells was already significantly reduced at MOI 10 (P ¼ 1.3 Â 10
À5
) by the Adeno_sh714 and 1390 adenoviruses in comparison with the Adeno-GFP, the Adeno-shControl or the uninfected controls at day 4, demonstrating that the biological effect was due to T-ag inhibition rather than to siRNA inhibition of BKV-induced tumors S Sabbioni et al a nonspecific or off-target effect ( Figure 2 ). These results demonstrate that shRNAs expressed by adenoviruses are able to suppress the expression of the target T-ag gene and significantly inhibit the growth of BKV-transformed cells. BKV T-ag binds to p53, causing its functional inactivation. We tested whether inhibition of T-ag expression could restore p53 activity. We assayed this possibility by the use of a reporter vector system responsive to p53. Indeed, cells infected with Adenosh1390 or Adeno-sh714 induced p53 activation as proven by the induction of transcriptional activity of the reporter vector system and by the transcriptional activation of the Mdm2 endogenous gene (Figure 3a and b) . We also analyzed the activation of caspase 3: the cleaved activated form was detectable at 24 h after cell infection (Figure 3c ). These results suggest that growth inhibition induced by anti-T-ag siRNAs was the consequence of p53-mediated apoptotic death.
Adenovirally expressed anti-T shRNA efficiently suppresses BKV-induced tumorigenic phenotype As expression of BKV T-ag is necessary to maintain the oncogenic phenotype of BKV-transformed cells, we investigated if anti-T-ag siRNAs, expressed by adenoviruses could suppress in vivo tumorigenicity of pRPc cells.
2 Â 10 5 pRPc cells were infected in vitro with a combination (1:1 ratio) of Adeno-sh1390 and Adenosh714 (the combination indicated as Adeno-shBKVT) at an MOI of 10 VPPF. Twenty-four hours later, the infected cells were injected subcutaneously into newborn syngenic BALB/c mice (11 animals). Control groups were injected with the same number of cells, either uninfected (eight mice), infected with Adeno-shControl (seven mice) or with Adeno-GFP viruses (seven mice). All controls developed a tumor at the site of injection, whereas only one out of 11 mice inoculated with the Adeno-shBKVTinfected cells developed a tumor. A detectable nodule appeared with a mean latency of 10 days (7À 2 days) in the control groups, whereas the single tumor in the experimental group appeared 19 days after inoculation and its growth was significantly reduced (Figure 4 ). These results demonstrate that adenovirus-mediated RNAi against BKV T-ag leads to suppression of tumorigenicity of BKV-transformed cells, while the adenovirus per se showed no apparent effect on tumorigenicity of these cells. 
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We next investigated whether the adenovirus vectors expressing anti-T shRNA could be employed as in vivo therapeutic agents. In one set of experiments, adenoviral vector injections were initiated 24 h after the subcutaneous injection of 2 Â 10 5 pRPc cells (eight animals). 5 Â 10 6 infectious units of a combination (1:1 ratio) of Adeno-sh1390 and Adeno-sh714 were injected every 3 days at the site of cell inoculation: no tumor nodules were detectable until day 21. Conversely, in the control groups (eight mock-transduced mice and six mice locally transduced with the Adeno-GFP), palpable tumor nodules appeared at days 10-11 after cell inoculation. At day 31, tumors of the experimental group were about fourfold (P ¼ 0.02) smaller than the tumors in the control groups (Figure 5a ). These results indicated that the virally expressed anti-BKV-T-ag siRNAs were effective in controlling the in vivo growth of tumors induced by BKV-transformed cells.
In a second set of experiments, we assayed the ability of adenoviral vectors to control or induce regression of the already detectable pRPc-induced tumors. Following the subcutaneous injection of 2 Â 10 5 uninfected pRPc cells into BALB/c newborns, intratumoral injection of adenoviruses was initiated at the appearance of a palpable nodule at day 10 (tumor diameter of 2-4 mm). 5 Â Adeno-sh714 (indicated as Adeno-shBKVT) were injected intratumorally every 2 days in seven mice. Growth of the tumors treated with the Adeno-shBKVT was significantly (P ¼ 0.03) reduced compared with the tumor injected with the Adeno-GFP (six mice) or with untreated controls (eight mice) (Figure 5b ). The smaller size of tumor nodules in mice treated with Adeno-shBKVT indicated that the anti-T-ag suppressing adenovirus could limit the growth of the tumor mass.
Discussion
The in vivo delivery of siRNA molecules remains an unsolved issue. An in vivo approach for delivering siRNA is the hydrodynamic injection method, 33 which achieves a high efficiency of liver delivery in the mouse model. Other promising delivery methods for an in vivo approach with potential clinical application include local and direct administration of siRNA to sequestered anatomical sites. 34, 35 The ability of viral vectors to efficiently transduce mammalian cells in vitro and in vivo coupled to their effectiveness in expressing transduced genes, make their use a feasible approach in humans. Retrovirus, lentivirus and adenovirus vectors, expressing siRNA, have been described. [36] [37] [38] Here, we report the development of an adenovirus vector system that expresses shRNAs that are functionally processed into active siRNAs against the T-ag oncogene of the human polyomavirus BK. The vector can be used to accommodate any other shRNA-producing cassette. In comparison with recently reported adenovirus vectors for the expression of shRNA, [38] [39] [40] [41] the adenoviral vector reported here can be easily manipulated to introduce any shRNAencoding gene.
We have used this adenovirus vector to target the BKV T-ag oncogene, with the aim of eliciting an antitumor effect. The results indicate that the Adeno-shBKVT vectors are able to efficiently express biologically active shRNA molecules and elicit a therapeutic effect by silencing the expression of BKV T-ag and inducing antitumor activity. Suppression of T-ag in the pRPc cells results in induction of apoptosis, indicating that inhibition of this process is a critical cellular mechanism involved in BKV transformation. T-ag interaction with the p53 tumor suppressor protein is the likely molecular mechanism involved in protection from apoptosis, which is disrupted by anti-T-ag siRNA.
In humans, the presence of BKV DNA and RNA in tumor cells, the ability of the viral genome or subgenomic fragments to immortalize human cells in vitro and the evidence that immortalization is due to BKV T-ag suggest that BKV may indeed cooperate as a cofactor in the induction and/or progression of human tumors. However, the lack of epidemiological and clinical evidence that viral infection represents a risk factor for tumor development still hinder a definitive conclusion. Other viral oncogenes could be targeted by this approach. For instance the highly homologous SV40 T-ag model system, whose association with human neoplasms has been reported by several investigators, 42 or the viral oncogenes associated with the human oncogenic papillomaviruses. Indeed, suppression of E6 expressed by HPV-16 or HPV-18 in human cell lines resulted in apoptotic cell death and in suppression of tumorigenicity. 43, 44 In spite of the fact that the role of BKV and SV40 in human tumors is still controversial, our results may have general significance. They prove that similar approaches can be used for in vivo targeting of activated oncogenes with the aim of suppressing tumorigenesis: if an activated oncogene critical for the oncogenic process is identified, it can be targeted and inhibited by using an adenovirusmediated siRNA delivery. Indeed, it has been reported that targeting of the BCR-ABL chimeric oncogene derived from the chromosomal translocation associated siRNA inhibition of BKV-induced tumors S Sabbioni et al with the Philadelphia (Ph) chromosome in chronic myeloid leukemia resulted in BCR/ABL knockdown and was accompanied by strong induction of in vitro apoptotic cell death. 45 Likewise, targeting an activated K-RAS oncogene has also been proven. 36 These studies proved the efficacy of the approach in specifically targeting activated oncogenes and proved that this approach can be highly selective, a critical element in anti-neoplastic therapeutic intervention. Our vector system can also potentially be used to target multiple oncogenes at the same time.
The limitation of this system is associated with the inefficient local infection of tumor cells. Indeed, histologic examination of the tumors transduced with adenovirus vectors revealed foci of regression surrounded by areas of cells in active proliferation, most likely because of the difficult diffusion of the adenovirus vector to the cells in the tumor mass. Hence, changes in the technology of intratumor delivery are necessary to improve viral infection of neoplastic cells. Interestingly, tumor surgical resection followed by local viral infection of tumor margins resulted in complete abrogation of tumor regrowth (data not shown), suggesting that combination of surgery and gene therapy approaches may provide the most effective therapeutic results. However, the most important drawback of our vector, common to other viral vector systems, is the unfeasibility of the use of this approach for systemic delivery, which hinders for example the therapeutic intervention on metastases. It has been recently reported that steroid and lipid conjugates of siRNAs can enhance cellular uptake and gene silencing in liver cells. Intravenous injection of these conjugates in mice resulted in silencing of the endogenous apoB messenger RNA in liver and jejunum with consequent decrease of plasma levels of apoB protein and cholesterol. Thus, siRNAs can be modified to increase their stability and enhance cellular uptake, 46 suggesting that it may become feasible for their use as therapeutic agents against cancer, infectious diseases and other human disorders.
